Pacira BioSciences Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution
Pacira BioSciences Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution
A number of Pacira BioSciences, Inc. (NASDAQ:PCRX) insiders sold their shares in the last year, which may have raised concerns among investors. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.
去年,许多帕西拉生物科学公司(纳斯达克股票代码:PCRX)内部人士出售了股票,这可能引起了投资者的担忧。在评估内幕交易时,了解内部人士是否在买入通常更有帮助,因为内幕卖出可以有多种解释。但是,当多个内部人士在特定期限内出售股票时,股东应注意,因为这可能是一个危险信号。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
尽管我们绝不会建议投资者仅根据公司董事的所作所为做出决定,但我们确实认为密切关注内部人士的所作所为是完全合乎逻辑的。
See our latest analysis for Pacira BioSciences
查看我们对 Pacira BioSciences 的最新分析
The Last 12 Months Of Insider Transactions At Pacira BioSciences
Pacira BioSciences 过去 12 个月的内幕交易
In the last twelve months, the biggest single sale by an insider was when the Advisor, David Stack, sold US$399k worth of shares at a price of US$38.99 per share. So what is clear is that an insider saw fit to sell at around the current price of US$35.48. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).
在过去的十二个月中,一位内部人士最大的一次出售是顾问大卫·斯塔克以每股38.99美元的价格出售了价值39.9万美元的股票。因此,显而易见的是,一位内部人士认为以当前35.48美元左右的价格卖出是合适的。虽然我们通常不喜欢看到内幕销售,但更令人担忧的是是否以较低的价格进行销售。在这种情况下,大甩卖是在当前价格左右进行的,因此还不错(但仍然不是积极的)。
Insiders in Pacira BioSciences didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
去年,Pacira BioSciences的内部人士没有购买任何股票。下图显示了去年的内幕交易(公司和个人)。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240109/0-8e202957b1659c75f9b0a9e0eb31fe8b-0-c22ed23aa363107769f5e9004a899ef3.png/big)
I will like Pacira BioSciences better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我看到一些重大的内幕收购,我会更喜欢Pacira BioSciences。在我们等待的同时,请查看这份免费清单,列出了最近有大量内幕收购的成长型公司。
Does Pacira BioSciences Boast High Insider Ownership?
Pacira BioSciences 是否拥有很高的内部所有权?
For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Pacira BioSciences insiders own about US$20m worth of shares. That equates to 1.3% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
对于普通股股东来说,值得检查一下公司内部人士持有多少股票。通常,内部人士的所有权越高,内部人士长期建立公司的可能性就越大。帕西拉生物科学内部人士拥有价值约2000万美元的股票。这相当于该公司的1.3%。尽管这是一个强劲但并不突出的内部所有权水平,但这足以表明管理层与小型股东之间有一定的一致性。
What Might The Insider Transactions At Pacira BioSciences Tell Us?
Pacira BioSciences的内幕交易能告诉我们什么?
It doesn't really mean much that no insider has traded Pacira BioSciences shares in the last quarter. Our analysis of Pacira BioSciences insider transactions leaves us cautious. But it's good to see that insiders own shares in the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. You'd be interested to know, that we found 2 warning signs for Pacira BioSciences and we suggest you have a look.
上个季度没有内部人士交易过Pacira BioSciences的股票,这并没有多大意义。我们对Pacira BioSciences内幕交易的分析使我们持谨慎态度。但很高兴看到内部人士拥有该公司的股份。因此,这些内幕交易可以帮助我们建立有关股票的论点,但也值得了解这家公司面临的风险。你可能会有兴趣知道,我们发现了 Pacira BioSciences 的两个警告信号,我们建议你看看。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,来看看这份有趣的公司的免费清单吧。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。